dehydroepiandrosterone has been researched along with Prostatic Neoplasms in 142 studies
Dehydroepiandrosterone: A major C19 steroid produced by the ADRENAL CORTEX. It is also produced in small quantities in the TESTIS and the OVARY. Dehydroepiandrosterone (DHEA) can be converted to TESTOSTERONE; ANDROSTENEDIONE; ESTRADIOL; and ESTRONE. Most of DHEA is sulfated (DEHYDROEPIANDROSTERONE SULFATE) before secretion.
dehydroepiandrosterone : An androstanoid that is androst-5-ene substituted by a beta-hydroxy group at position 3 and an oxo group at position 17. It is a naturally occurring steroid hormone produced by the adrenal glands.
Prostatic Neoplasms: Tumors or cancer of the PROSTATE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "DHEA levels in patients with prostatic cancer were significantly lower, but total and free testosterone (T) significantly higher as those in an age-matched control group." | 5.28 | Dehydroepiandrosterone (DHEA) levels in patients with prostatic cancer, heart diseases and under surgery stress. ( Dörner, G; Pilz, C; Schnorr, D; Stahl, F, 1992) |
| " Prostate adenocarcinomas were induced in male Wistar-Unilever rats by a sequential regimen of cyproterone acetate and testosterone propionate, followed by a single i." | 3.70 | Chemoprevention of rat prostate carcinogenesis by early and delayed administration of dehydroepiandrosterone. ( Bosland, MC; Johnson, WD; Kelloff, GJ; Lubet, RA; McCormick, DL; Rao, KV; Steele, VE, 1999) |
| "Forty patients with metastatic adenocarcinoma of the prostate were evaluated for response to treatment with aminoglutethimide plus cortisone acetate." | 3.67 | Response to aminoglutethimide and cortisone acetate in advanced prostatic cancer. ( Chilvers, CE; Dowsett, M; Easton, D; Jeffcoate, SL; Miller, J; Pocock, RD; Ponder, BA; Shearer, RJ, 1984) |
| "The conversion of dehydroepiandrosterone sulfate into testosterone, delta4-androstenedione, and dihydrotestosterone has been measured in minced prostatic adenocarcinoma tissue from three untreated patients, two patients treated with diethylstilbestrol, and one treated with cyproterone acetate." | 3.65 | Biosynthesis and metabolism of androgenic hormones in cancer of the prostate. ( Di Silverio, F; Gagliardi, V; Sciarra, F; Sorcini, G, 1976) |
| "17α-ethynyl-5α-androstane-3α, 17β-diol (HE3235, Apoptone) is an orally bioavailable synthetic analogue of 3β-androstanediol, that is active in rodent models of prostate and breast cancer, and is in Phase IIa clinical trials for the treatment of early- and late-stage prostate cancer." | 2.77 | 17α-alkynyl 3α, 17β-androstanediol non-clinical and clinical pharmacology, pharmacokinetics and metabolism. ( Ahlem, C; Bell, D; Delorme, E; Frincke, J; Kennedy, M; Page, T; Reading, C; Stickney, D; Villegas, S; White, S, 2012) |
| "Fifty-nine patients with breast cancer and 10 with prostate cancer enrolled in an eight-week Mindfulness-Based Stress Reduction (MBSR) program that incorporated relaxation, meditation, gentle yoga, and daily home practice." | 2.71 | Mindfulness-based stress reduction in relation to quality of life, mood, symptoms of stress and levels of cortisol, dehydroepiandrosterone sulfate (DHEAS) and melatonin in breast and prostate cancer outpatients. ( Carlson, LE; Goodey, E; Patel, KD; Speca, M, 2004) |
| "Our results suggest that a decrease in prostate cancer risk with alpha-tocopherol is likely to occur through a mechanism that is nonhormonal and independent of IGF-1." | 2.71 | The modulation of prostate cancer risk with alpha-tocopherol: a pilot randomized, controlled clinical trial. ( Basler, JW; Fernandes, G; Hernáandez, J; Syed, S; Thompson, IM; Troyer, DA; von Merveldt, D; Weiss, G, 2005) |
| "Only one patient has died from prostate cancer while 3 have died from other causes." | 2.66 | Combination therapy with flutamide and castration (LHRH agonist or orchiectomy) in advanced prostate cancer: a marked improvement in response and survival. ( Belanger, A; Bergeron, V; Dupont, A; Emond, J; Giguere, M; Labrie, F; Lacoursiere, Y; Monfette, G, 1985) |
| "Androgen blockade-naïve prostate cancer (PCa) develops into CRPC during androgen deprivation therapy (ADT) by various genetic actions." | 2.52 | Reconsideration of progression to CRPC during androgen deprivation therapy. ( Mizokami, A; Namiki, M, 2015) |
| "The possibility of an increased risk of prostate cancer for healthy men has also been suggested on theoretical basis but recent experimental data showed that androgens may act in prevention of prostate cancer." | 2.42 | Prevention of prostate cancer by androgens: experimental paradox or clinical reality. ( Algarté-Génin, M; Costa, P; Cussenot, O, 2004) |
| "A patient with advanced prostate cancer with progressive symptomatology was treated with DHEA after other treatment regimens failed." | 2.40 | Use of DHEA in a patient with advanced prostate cancer: a case report and review. ( Jones, JA; Leidich, RB; Nguyen, A; Straub, M; Veech, RL; Wolf, S, 1997) |
| "Under castration-resistant prostate cancer conditions, androstenedione was significantly associated with testosterone levels, suggesting the presence of tumor-related circulating androgens in these patients." | 1.72 | Extensive Alteration of Androgen Precursor Levels After Castration in Prostate Cancer Patients and Their Association With Active Androgen Level. ( Caron, P; Guillemette, C; Lacombe, L; Lévesque, É; Morin, F; Neveu, B; Pouliot, F; Rouleau, M; Toren, P; Turcotte, V, 2022) |
| "Androgens are essential for prostate cancer development." | 1.62 | Tracing steroidogenesis in prostate biopsy samples to unveil prostate tissue androgen metabolism characteristics and potential clinical application. ( Bian, C; Chen, L; Chen, X; Gao, Y; Hou, Z; Huang, S; Hydyr, N; Le, W; Li, Z; Lian, J; Liu, Y; Mei, Z; Tan, Q; Wu, D; Xu, C; Yang, T; Zhang, S; Zhu, X, 2021) |
| "Bone metastasis is a complication of prostate cancer in up to 90% of men afflicted with advanced disease." | 1.62 | Osteoblasts Generate Testosterone From DHEA and Activate Androgen Signaling in Prostate Cancer Cells. ( Al-Barghouthi, BM; Auchus, RJ; Clines, GA; Clines, KL; Farber, CR; Farber, EA; Moon, HH; O'Day, PJ, 2021) |
| "Most patients with prostate cancer receiving enzalutamide or abiraterone develop resistance." | 1.56 | Steroid Sulfatase Stimulates Intracrine Androgen Synthesis and is a Therapeutic Target for Advanced Prostate Cancer. ( Armstrong, CM; D'Abronzo, LS; Evans, CP; Gao, AC; Li, PK; Liu, C; Liu, L; Lombard, AP; Lou, W; Ning, S; Yang, JC; Zhao, J; Zhao, R, 2020) |
| "Serum PSA levels in prostate cancer patients were also significantly associated with high Gleason score and advanced clinical stage." | 1.43 | Low serum dehydroepiandrosterone examined by liquid chromatography-tandem mass spectrometry correlates with poor prognosis in hormone-naïve prostate cancer. ( Harada, M; Honma, S; Ichikawa, T; Kubota, Y; Masumori, N; Miyoshi, Y; Mizokami, A; Nonomura, N; Sakai, H; Sakamaki, K; Shibata, Y; Sugimura, Y; Suzuki, K; Taguri, M; Uemura, H; Umemoto, S, 2016) |
| "Adrenal androgens can be metabolized by prostate cancer cells, which is one of the mechanisms associated with progression to castration-resistant prostate cancer (CRPC)." | 1.39 | Aldo-keto reductase family 1 member C3 (AKR1C3) is a biomarker and therapeutic target for castration-resistant prostate cancer. ( Brandt, A; Hamid, AR; Pfeiffer, MJ; Schaafsma, E; Schalken, JA; Sedelaar, JP; Sweep, FC; Verhaegh, GW, 2013) |
| "The levels of adrenal androgens in prostate cancer tissues after ADT were similar to those in untreated PCa." | 1.37 | Effect of castration monotherapy on the levels of adrenal androgens in cancerous prostatic tissues. ( Arai, S; Honma, S; Kobayashi, M; Miyashiro, Y; Shibata, Y; Suzuki, K; Tomaru, Y, 2011) |
| "Relapse of castration-resistant prostate cancer (CRPC) that occurs after androgen deprivation therapy of primary prostate cancer can be mediated by reactivation of the androgen receptor (AR)." | 1.37 | Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors. ( Balk, SP; Bubley, GJ; Cai, C; Chen, S; Marck, B; Matsumoto, AM; Mostaghel, EA; Nelson, PS; Ng, P; Simon, NI; Wang, H, 2011) |
| "When prostate cancer-associated (6S) stromal cells were added in coculture, DHEA stimulated LAPC-4 cell PSA protein secretion to levels approaching induction by DHT." | 1.35 | Human prostate stromal cells stimulate increased PSA production in DHEA-treated prostate cancer epithelial cells. ( Arnold, JT; Blackman, MR; Cheung, PW; Gray, NE; Jacobowitz, K; Le, H; McFann, KK; Viswanathan, L, 2008) |
| "LAPC-4 prostate cancer cells were grown in coculture with prostate stromal cells (6S) and treated with DHEA +/- TGFbeta1 or interleukin-6." | 1.35 | Endocrine-immune-paracrine interactions in prostate cells as targeted by phytomedicines. ( Arnold, JT; Blackman, MR; Choi, R; Gray, NE; Liu, X, 2009) |
| "LNCaP and LAPC-4 prostate cancer cells were used to determine whether DHEA-modulated proliferation and prostate specific antigen (PSA) production were mediated via the androgen receptor (AR) and/or ERbeta." | 1.34 | Androgen receptor or estrogen receptor-beta blockade alters DHEA-, DHT-, and E(2)-induced proliferation and PSA production in human prostate cancer cells. ( Allen, JD; Arnold, JT; Blackman, MR; Le, H; Liu, X; McFann, KK, 2007) |
| " Chronic administration of fluasterone at levels of 2000 and 1000 mg/kg diet reduced the incidence of adenocarcinoma in the dorsolateral/anterior prostate from 64% in dietary controls to 28 and 31%, respectively." | 1.34 | Chemoprevention of rat prostate carcinogenesis by dietary 16alpha-fluoro-5-androsten-17-one (fluasterone), a minimally androgenic analog of dehydroepiandrosterone. ( Bosland, MC; Johnson, WD; Kozub, NM; Lubet, RA; McCormick, DL; Rao, KV; Steele, VE, 2007) |
| "The steroid-responsive human LNCaP prostate cancer cells, containing a functional but mutated androgen receptor (AR), were used to compare effects of DHEA with those of T, DHT, and E2 on cell proliferation and protein and/or gene expression of AR, prostate-specific antigen (PSA), IGF-I, IGF-I receptor (IGF-IR), IGF-II, IGF-binding proteins-2, -3, and -5, (IGFBPs-2, -3, and -5), and estrogen receptor-beta (ERbeta)." | 1.33 | Comparative effects of DHEA vs. testosterone, dihydrotestosterone, and estradiol on proliferation and gene expression in human LNCaP prostate cancer cells. ( Arnold, JT; Blackman, MR; Le, H; McFann, KK, 2005) |
| "Novel therapies for recurrent prostate cancer should target androgen receptor directly and prevent the formation of androgens within prostate cancer tissue." | 1.32 | The androgen axis in recurrent prostate cancer. ( Ford, OH; French, FS; Gregory, CW; Kim, D; Mohler, JL; Petrusz, P; Weaver, CM; Wilson, EM, 2004) |
| "Treatment with dehydroepiandrosterone pellets, which produced clinical castration levels of serum testosterone, accelerated the MDA PCa 2b-hr but not MDA PCa 2b tumor growth in castrated mice and increased blood prostate-specific antigen levels in castrated mice bearing MDA PCa 2b-hr tumors but not in mice bearing MDA PCa 2b tumors." | 1.32 | Enhanced androgen receptor signaling correlates with the androgen-refractory growth in a newly established MDA PCa 2b-hr human prostate cancer cell subline. ( Araki, H; Hara, T; Kusaka, M; Nakamura, K; Yamaoka, M, 2003) |
| "Patients with high Gleason score prostate cancer have lower testosterone and estradiol serum levels." | 1.31 | High-grade prostate cancer is associated with low serum testosterone levels. ( Haitel, A; Kramer, G; Madersbacher, S; Marberger, M; Schatzl, G; Thurridl, T; Waldmüller, J, 2001) |
| "No effect on the development of the prostate cancer precursor lesions (prostate intraepithelial neoplasia) was observed when mice were treated with DHEA, DFMO, tocopherol acetate, selenomethionine, or 9-cis-retinoic acid, although the effects on late-stage prostate cancer development were not determined." | 1.31 | 2-difluoromethylornithine and dehydroepiandrosterone inhibit mammary tumor progression but not mammary or prostate tumor initiation in C3(1)/SV40 T/t-antigen transgenic mice. ( Anver, MR; Green, JE; Kelloff, G; Lubet, R; Moon, RC; Shibata, E; Shibata, MA, 2001) |
| "This regimen reproducibly induces prostate cancers in high incidence, with no gross toxicity and a low incidence of neoplasia in the seminal vesicle and other non-target tissues." | 1.30 | Chemoprevention of hormone-dependent prostate cancer in the Wistar-Unilever rat. ( McCormick, DL; Rao, KV, 1999) |
| "Cultures from high grade prostatic intraepithelial neoplasia (HGPIN) have been established and immortalized by HPV-18 infection." | 1.30 | Growth of HPV-18 immortalized human prostatic intraepithelial neoplasia cell lines. Influence of IL-10, follistatin, activin-A, and DHT. ( Garcia, FU; Liu, A; Rhim, JS; Stearns, ME; Wang, M, 1999) |
| "In addition, the risk of prostate cancer is related to serum levels of vitamin D-binding protein (VDBP) and total dehydroepiandrosterone and to polymorphic variation in VDBP." | 1.29 | Seasonal variation in vitamin D, vitamin D-binding protein, and dehydroepiandrosterone: risk of prostate cancer in black and white men. ( Corder, EH; Friedman, GD; Orentreich, N; Vogelman, JH, 1995) |
| "The major focus in prostate cancer therapy currently is the role of the adrenal androgens." | 1.29 | Basis for hormonal management of advanced prostate cancer. ( Geller, J, 1993) |
| "DHEA levels in patients with prostatic cancer were significantly lower, but total and free testosterone (T) significantly higher as those in an age-matched control group." | 1.28 | Dehydroepiandrosterone (DHEA) levels in patients with prostatic cancer, heart diseases and under surgery stress. ( Dörner, G; Pilz, C; Schnorr, D; Stahl, F, 1992) |
| "Proliferation of all AXC/SSh prostate cancer cell lines during propagation on media containing fetal bovine serum was not altered by changes in media testosterone concentration through the range 10(-6) to 10(-9) M." | 1.27 | Differential androgen modulation of AXC/SSh rat prostate cancer cell proliferation in vitro and its antagonism by antiandrogen. ( Huot, RI; Shain, SA, 1986) |
| "Ketoconazole can suppress androgen production and has a beneficial role in the hormonal therapy of patients with prostate cancer who have not undergone orchiectomy." | 1.27 | High-dose ketoconazole therapy in patients with metastatic prostate cancer. ( Al-Sarraf, M; Decker, DA; Kresge, C; Subramanian, MG; Tapazoglou, E, 1986) |
| "Ten castrated patients with prostatic cancer received flutamide (FLU) alone for 2 months and, afterwards, the combined therapy of FLU and AG for 2 months." | 1.27 | Effects of flutamide and aminoglutethimide on plasma 5 alpha-reduced steroid glucuronide concentrations in castrated patients with cancer of the prostate. ( Bélanger, A; Brochu, M; Cusan, L; Dupont, A; Labrie, F, 1987) |
| "Ketoconazole is an antifungal agent that, in high doses, inhibits testicular and adrenal steroid synthesis." | 1.27 | Steroid synthesis inhibition by ketoconazole: sites of action. ( Trachtenberg, J; Zadra, J, 1988) |
| "In these prostatic cancer patients, plasma androgen levels decreased, while estrogen levels increased." | 1.26 | Effect of diet on plasma and urinary hormones in South African black men with prostatic cancer. ( Garbaczewski, L; Hill, P; Walker, AR; Wynder, EL, 1982) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 44 (30.99) | 18.7374 |
| 1990's | 27 (19.01) | 18.2507 |
| 2000's | 30 (21.13) | 29.6817 |
| 2010's | 28 (19.72) | 24.3611 |
| 2020's | 13 (9.15) | 2.80 |
| Authors | Studies |
|---|---|
| Ventura-Bahena, A | 1 |
| Hernández-Pérez, JG | 1 |
| Torres-Sánchez, L | 1 |
| Sierra-Santoyo, A | 1 |
| Escobar-Wilches, DC | 1 |
| Escamilla-Núñez, C | 1 |
| Gómez, R | 1 |
| Rodríguez-Covarrubias, F | 1 |
| López-González, ML | 1 |
| Figueroa, M | 1 |
| Urbanek, KA | 1 |
| Kowalska, K | 1 |
| Habrowska-Górczyńska, DE | 1 |
| Domińska, K | 1 |
| Sakowicz, A | 1 |
| Piastowska-Ciesielska, AW | 1 |
| Moyad, MA | 1 |
| Chu, L | 1 |
| Shu, X | 1 |
| Huang, Y | 1 |
| Chu, T | 1 |
| Ge, M | 1 |
| Lu, Q | 1 |
| Rouleau, M | 1 |
| Neveu, B | 1 |
| Caron, P | 1 |
| Morin, F | 1 |
| Toren, P | 1 |
| Lacombe, L | 1 |
| Turcotte, V | 1 |
| Lévesque, É | 1 |
| Guillemette, C | 1 |
| Pouliot, F | 1 |
| Miyoshi, Y | 2 |
| Kawahara, T | 1 |
| Uemura, H | 2 |
| McManus, JM | 1 |
| Chung, YM | 1 |
| Sharifi, N | 5 |
| Mafla-España, MA | 1 |
| Torregrosa, MD | 1 |
| Beamud-Cortés, M | 1 |
| Bermell-Marco, L | 1 |
| Rubio-Briones, J | 1 |
| Cauli, O | 1 |
| DE Luca, S | 1 |
| Amante, E | 1 |
| Fiori, C | 1 |
| Alleva, G | 1 |
| Alladio, E | 1 |
| Marini, F | 1 |
| Garrou, D | 1 |
| Manfredi, M | 1 |
| Amparore, D | 1 |
| Checcucci, E | 1 |
| Pruner, S | 1 |
| Salomone, A | 1 |
| Scarpa, RM | 1 |
| Vincenti, M | 1 |
| Porpiglia, F | 1 |
| Cheong, EJY | 1 |
| Nair, PC | 1 |
| Neo, RWY | 1 |
| Tu, HT | 1 |
| Lin, F | 1 |
| Chiong, E | 1 |
| Esuvaranathan, K | 1 |
| Fan, H | 1 |
| Szmulewitz, RZ | 1 |
| Peer, CJ | 1 |
| Figg, WD | 1 |
| Chai, CLL | 1 |
| Miners, JO | 1 |
| Chan, ECY | 1 |
| Armstrong, CM | 1 |
| Liu, C | 1 |
| Liu, L | 1 |
| Yang, JC | 1 |
| Lou, W | 1 |
| Zhao, R | 1 |
| Ning, S | 1 |
| Lombard, AP | 1 |
| Zhao, J | 1 |
| D'Abronzo, LS | 1 |
| Evans, CP | 1 |
| Li, PK | 1 |
| Gao, AC | 1 |
| Hou, Z | 1 |
| Yang, T | 1 |
| Mei, Z | 1 |
| Zhang, S | 1 |
| Gao, Y | 1 |
| Chen, X | 1 |
| Tan, Q | 1 |
| Zhu, X | 1 |
| Xu, C | 1 |
| Lian, J | 1 |
| Bian, C | 1 |
| Liu, Y | 1 |
| Le, W | 1 |
| Hydyr, N | 1 |
| Wu, D | 1 |
| Chen, L | 1 |
| Huang, S | 1 |
| Li, Z | 1 |
| Moon, HH | 1 |
| Clines, KL | 1 |
| O'Day, PJ | 1 |
| Al-Barghouthi, BM | 1 |
| Farber, EA | 1 |
| Farber, CR | 1 |
| Auchus, RJ | 3 |
| Clines, GA | 1 |
| Hettel, D | 1 |
| Zhang, A | 1 |
| Alyamani, M | 1 |
| Berk, M | 1 |
| Hamid, ARAH | 1 |
| Tendi, W | 1 |
| Sesari, SS | 1 |
| Mochtar, CA | 1 |
| Umbas, R | 1 |
| Verhaegh, G | 1 |
| Schalken, JA | 2 |
| Wu, Y | 1 |
| Tang, L | 1 |
| Azabdaftari, G | 1 |
| Pop, E | 1 |
| Smith, GJ | 1 |
| Ishizaki, F | 2 |
| Nishiyama, T | 2 |
| Kawasaki, T | 1 |
| Miyashiro, Y | 3 |
| Hara, N | 2 |
| Takizawa, I | 2 |
| Naito, M | 1 |
| Takahashi, K | 2 |
| Du, JJ | 1 |
| Chen, HL | 1 |
| Li, YC | 1 |
| Anagnostopoulou, V | 1 |
| Pediaditakis, I | 1 |
| Alkahtani, S | 1 |
| Alarifi, SA | 1 |
| Schmidt, EM | 1 |
| Lang, F | 1 |
| Gravanis, A | 1 |
| Charalampopoulos, I | 1 |
| Stournaras, C | 1 |
| Piao, YS | 1 |
| Wiesenfeld, P | 1 |
| Sprando, R | 1 |
| Arnold, JT | 7 |
| Doherty, D | 1 |
| Dvorkin, SA | 1 |
| Rodriguez, EP | 1 |
| Thompson, PD | 1 |
| Audenet, F | 1 |
| Murez, T | 1 |
| Ripert, T | 1 |
| Villers, A | 1 |
| Neuzillet, Y | 1 |
| Mizokami, A | 3 |
| Namiki, M | 2 |
| Wilton, JH | 1 |
| Titus, MA | 1 |
| Efstathiou, E | 1 |
| Fetterly, GJ | 1 |
| Mohler, JL | 3 |
| Labrie, F | 10 |
| Bratoeff, E | 1 |
| Garrido, M | 1 |
| Ramírez-Apan, T | 1 |
| Heuze, Y | 1 |
| Sánchez, A | 1 |
| Soriano, J | 1 |
| Cabeza, M | 1 |
| Li, L | 1 |
| Fath, MA | 1 |
| Scarbrough, PM | 1 |
| Watson, WH | 1 |
| Spitz, DR | 1 |
| Nakai, Y | 1 |
| Tanaka, N | 1 |
| Anai, S | 1 |
| Miyake, M | 1 |
| Tatsumi, Y | 1 |
| Fujimoto, K | 1 |
| Umemoto, S | 1 |
| Sakamaki, K | 1 |
| Taguri, M | 1 |
| Suzuki, K | 3 |
| Shibata, Y | 2 |
| Masumori, N | 1 |
| Ichikawa, T | 1 |
| Sugimura, Y | 1 |
| Nonomura, N | 1 |
| Sakai, H | 1 |
| Honma, S | 3 |
| Harada, M | 1 |
| Kubota, Y | 1 |
| Gray, NE | 2 |
| Jacobowitz, K | 1 |
| Viswanathan, L | 1 |
| Cheung, PW | 1 |
| McFann, KK | 3 |
| Le, H | 3 |
| Blackman, MR | 5 |
| Liu, X | 2 |
| Choi, R | 1 |
| Koh, E | 1 |
| Izumi, K | 1 |
| Narimoto, K | 1 |
| Takeda, M | 1 |
| Dai, J | 1 |
| Keller, ET | 1 |
| Evaul, K | 2 |
| Li, R | 2 |
| Papari-Zareei, M | 1 |
| Brown, I | 1 |
| Cascio, MG | 1 |
| Wahle, KW | 1 |
| Smoum, R | 1 |
| Mechoulam, R | 1 |
| Ross, RA | 1 |
| Pertwee, RG | 1 |
| Heys, SD | 1 |
| Ahlem, C | 1 |
| Kennedy, M | 1 |
| Page, T | 1 |
| Bell, D | 1 |
| Delorme, E | 1 |
| Villegas, S | 1 |
| Reading, C | 1 |
| White, S | 1 |
| Stickney, D | 1 |
| Frincke, J | 1 |
| Hoshii, T | 1 |
| Arai, S | 1 |
| Tomaru, Y | 1 |
| Kobayashi, M | 3 |
| Cai, C | 1 |
| Chen, S | 2 |
| Ng, P | 1 |
| Bubley, GJ | 1 |
| Nelson, PS | 1 |
| Mostaghel, EA | 1 |
| Marck, B | 1 |
| Matsumoto, AM | 1 |
| Simon, NI | 1 |
| Wang, H | 1 |
| Balk, SP | 1 |
| Kaku, T | 1 |
| Hitaka, T | 1 |
| Ojida, A | 1 |
| Matsunaga, N | 1 |
| Adachi, M | 1 |
| Tanaka, T | 1 |
| Hara, T | 2 |
| Yamaoka, M | 2 |
| Kusaka, M | 2 |
| Okuda, T | 1 |
| Asahi, S | 1 |
| Furuya, S | 1 |
| Tasaka, A | 1 |
| Woodard, G | 1 |
| Ahmed, S | 1 |
| Podelski, V | 1 |
| Hernandez-Boussard, T | 1 |
| Presti, J | 1 |
| Morton, JM | 1 |
| Sharma, KK | 1 |
| Chang, KH | 1 |
| Yoshimoto, J | 1 |
| Liu, J | 1 |
| Hamid, AR | 1 |
| Pfeiffer, MJ | 1 |
| Verhaegh, GW | 1 |
| Schaafsma, E | 1 |
| Brandt, A | 1 |
| Sweep, FC | 1 |
| Sedelaar, JP | 1 |
| Kamrath, C | 1 |
| Hartmann, MF | 1 |
| Wudy, S | 1 |
| Belaisch, J | 1 |
| Miyamoto, H | 2 |
| Marwah, P | 3 |
| Marwah, A | 2 |
| Lardy, H | 3 |
| Chang, C | 2 |
| BRADSHAW, LR | 1 |
| BAGNESS, JE | 1 |
| PYRAH, LN | 1 |
| RAPER, FP | 1 |
| Nakamura, K | 1 |
| Araki, H | 1 |
| Oka, H | 1 |
| Negoro, H | 1 |
| Sugino, Y | 1 |
| Iwamura, H | 1 |
| Moroi, S | 1 |
| Kawakita, M | 1 |
| Carlson, LE | 1 |
| Speca, M | 1 |
| Patel, KD | 1 |
| Goodey, E | 1 |
| Gregory, CW | 2 |
| Ford, OH | 1 |
| Kim, D | 1 |
| Weaver, CM | 1 |
| Petrusz, P | 1 |
| Wilson, EM | 2 |
| French, FS | 2 |
| Christov, KT | 1 |
| Moon, RC | 2 |
| Lantvit, DD | 1 |
| Boone, CW | 1 |
| Kelloff, GJ | 2 |
| Steele, VE | 3 |
| Lubet, RA | 3 |
| Pezzuto, JM | 1 |
| Algarté-Génin, M | 1 |
| Cussenot, O | 1 |
| Costa, P | 1 |
| Bradlow, HL | 1 |
| Sepkovic, DW | 1 |
| Hernáandez, J | 1 |
| Syed, S | 1 |
| Weiss, G | 1 |
| Fernandes, G | 1 |
| von Merveldt, D | 1 |
| Troyer, DA | 1 |
| Basler, JW | 1 |
| Thompson, IM | 1 |
| Luu-The, V | 2 |
| Bélanger, A | 8 |
| Lin, SX | 1 |
| Simard, J | 2 |
| Pelletier, G | 1 |
| Labrie, C | 2 |
| McCormick, DL | 3 |
| Johnson, WD | 2 |
| Kozub, NM | 1 |
| Rao, KV | 3 |
| Bosland, MC | 2 |
| van Veldhuizen, PJ | 1 |
| Thrasher, JB | 1 |
| Ray, G | 1 |
| Cherian, R | 1 |
| Ward, J | 1 |
| Holzbeierlein, J | 1 |
| Gutow, S | 1 |
| Banerjee, SK | 1 |
| Allen, JD | 1 |
| Galvão, DA | 1 |
| Nosaka, K | 1 |
| Taaffe, DR | 1 |
| Peake, J | 1 |
| Spry, N | 1 |
| Yamaya, K | 1 |
| McGuigan, MR | 1 |
| Kristjanson, LJ | 1 |
| Newton, RU | 1 |
| Moreira, VM | 1 |
| Vasaitis, TS | 1 |
| Njar, VC | 1 |
| Salvador, JA | 1 |
| Borugian, MJ | 1 |
| Spinelli, JJ | 1 |
| Sun, Z | 1 |
| Kolonel, LN | 1 |
| Oakley-Girvan, I | 1 |
| Pollak, MD | 1 |
| Whittemore, AS | 1 |
| Wu, AH | 1 |
| Gallagher, RP | 1 |
| Dupont, A | 5 |
| Hill, P | 1 |
| Wynder, EL | 2 |
| Garbaczewski, L | 1 |
| Walker, AR | 1 |
| Vermeulen, A | 1 |
| Schelfhout, W | 1 |
| De Sy, W | 1 |
| Parker, L | 1 |
| Lai, M | 1 |
| Wolk, F | 1 |
| Lifrak, E | 1 |
| Kim, S | 1 |
| Epstein, L | 1 |
| Hadley, D | 1 |
| Miller, J | 2 |
| Ponder, BA | 1 |
| Shearer, RJ | 1 |
| Pocock, RD | 1 |
| Easton, D | 1 |
| Chilvers, CE | 1 |
| Dowsett, M | 1 |
| Jeffcoate, SL | 1 |
| Valenti, G | 1 |
| Banchini, A | 1 |
| Denti, L | 1 |
| Zavaroni, D | 1 |
| Trachtenberg, J | 2 |
| Lukkarinen, O | 1 |
| Hammond, GL | 1 |
| Kontturi, M | 1 |
| Vihko, R | 1 |
| Morioka, M | 1 |
| Geller, J | 4 |
| Culig, Z | 1 |
| Hobisch, A | 1 |
| Cronauer, MV | 1 |
| Cato, AC | 1 |
| Hittmair, A | 1 |
| Radmayr, C | 1 |
| Eberle, J | 1 |
| Bartsch, G | 2 |
| Klocker, H | 2 |
| Decensi, A | 1 |
| Torrisi, R | 1 |
| Marroni, P | 1 |
| Pensa, F | 1 |
| Padovani, P | 1 |
| Boccardo, F | 1 |
| Corder, EH | 1 |
| Friedman, GD | 1 |
| Vogelman, JH | 1 |
| Orentreich, N | 1 |
| Tan, J | 1 |
| Sharief, Y | 1 |
| Hamil, KG | 1 |
| Zang, DY | 1 |
| Sar, M | 1 |
| Gumerlock, PH | 1 |
| deVere White, RW | 1 |
| Pretlow, TG | 1 |
| Harris, SE | 1 |
| McNeil, C | 1 |
| Jones, JA | 1 |
| Nguyen, A | 1 |
| Straub, M | 1 |
| Leidich, RB | 1 |
| Veech, RL | 1 |
| Wolf, S | 1 |
| Uno, M | 1 |
| Deguchi, T | 1 |
| Ehara, H | 1 |
| Ishihara, S | 1 |
| Kobayashi, S | 1 |
| Goldberg, M | 1 |
| Wang, M | 1 |
| Liu, A | 1 |
| Garcia, FU | 1 |
| Rhim, JS | 1 |
| Stearns, ME | 1 |
| Chang, HC | 1 |
| Yeh, S | 1 |
| Huang, KE | 1 |
| Schatzl, G | 2 |
| Reiter, WJ | 1 |
| Thürridl, T | 2 |
| Waldmüller, J | 2 |
| Roden, M | 1 |
| Söregi, S | 1 |
| Madersbacher, S | 2 |
| Hartman, TJ | 1 |
| Dorgan, JF | 1 |
| Woodson, K | 1 |
| Virtamo, J | 1 |
| Tangrea, JA | 1 |
| Heinonen, OP | 1 |
| Taylor, PR | 1 |
| Barrett, MJ | 1 |
| Albanes, D | 1 |
| Kramer, G | 1 |
| Haitel, A | 1 |
| Marberger, M | 1 |
| Green, JE | 1 |
| Shibata, MA | 1 |
| Shibata, E | 1 |
| Anver, MR | 1 |
| Kelloff, G | 1 |
| Lubet, R | 1 |
| Takezawa, Y | 1 |
| Nakata, S | 1 |
| Kosaku, N | 1 |
| Fukabori, Y | 1 |
| Yamanaka, H | 2 |
| Walsh, PC | 2 |
| Siiteri, PK | 1 |
| Di Silverio, F | 2 |
| Gagliardi, V | 2 |
| Sorcini, G | 2 |
| Sciarra, F | 2 |
| Kisliakova, ND | 1 |
| Luntovskaia, VA | 1 |
| Polianichko, MF | 1 |
| Volovel'skiĭ, IZ | 1 |
| Albert, J | 1 |
| Yen, SS | 1 |
| Hill, PB | 1 |
| Nishida, S | 1 |
| Matsumura, S | 1 |
| Horino, M | 1 |
| Matsuki, M | 1 |
| Oyama, H | 1 |
| Tenku, A | 1 |
| Kakita, K | 1 |
| Tanaka, H | 1 |
| Omukai, Y | 1 |
| Stahl, F | 1 |
| Schnorr, D | 1 |
| Pilz, C | 1 |
| Dörner, G | 1 |
| van Weerden, WM | 3 |
| van Kreuningen, A | 3 |
| Elissen, NM | 1 |
| de Jong, FH | 3 |
| van Steenbrugge, GJ | 3 |
| Schröder, FH | 3 |
| Sasagawa, I | 2 |
| Satomi, S | 2 |
| La Rocca, RV | 1 |
| Danesi, R | 1 |
| Cooper, MR | 1 |
| Jamis-Dow, CA | 1 |
| Ewing, MW | 1 |
| Linehan, WM | 1 |
| Myers, CE | 1 |
| Moerings, EP | 2 |
| Schiller, CD | 1 |
| Schneider, MR | 1 |
| Hartmann, H | 1 |
| Graf, AH | 1 |
| Brochu, M | 4 |
| Lacoste, D | 1 |
| Noël, C | 1 |
| Cusan, L | 3 |
| Caron, S | 1 |
| Couture, J | 1 |
| Ayub, M | 1 |
| Levell, MJ | 1 |
| Carlström, K | 3 |
| Stege, R | 3 |
| Schürmeyer, T | 1 |
| Graff, J | 1 |
| Senge, T | 1 |
| Nieschlag, E | 1 |
| Katayama, T | 1 |
| Collste, L | 1 |
| Eriksson, A | 2 |
| Henriksson, P | 2 |
| Pousette, A | 1 |
| von Schoultz, B | 1 |
| Huot, RI | 2 |
| Shain, SA | 2 |
| Klein, H | 1 |
| Bressel, M | 1 |
| Kastendieck, H | 1 |
| Voigt, KD | 1 |
| Albert, JD | 1 |
| Giguere, M | 1 |
| Lacoursiere, Y | 1 |
| Emond, J | 1 |
| Monfette, G | 1 |
| Bergeron, V | 1 |
| Cliche, J | 1 |
| Imai, K | 1 |
| Kumasaka, F | 1 |
| Suzuki, T | 1 |
| Takahashi, O | 1 |
| Tapazoglou, E | 1 |
| Subramanian, MG | 1 |
| Al-Sarraf, M | 1 |
| Kresge, C | 1 |
| Decker, DA | 1 |
| De Coster, R | 1 |
| Caers, I | 1 |
| Coene, MC | 1 |
| Amery, W | 1 |
| Beerens, D | 1 |
| Haelterman, C | 1 |
| Zadra, J | 1 |
| Tomić, R | 1 |
| Ljungberg, B | 1 |
| Damber, JE | 1 |
| Farnsworth, WE | 1 |
| Oshima, H | 1 |
| Sarada, T | 2 |
| Ochi-Ai, K | 1 |
| Tamaoki, BI | 1 |
| Garnham, JR | 1 |
| Bulbrook, RD | 1 |
| Wang, DY | 1 |
| Bird, CE | 1 |
| Clark, AF | 1 |
| Yanaihara, T | 1 |
| Troen, P | 1 |
| Gurpide, E | 1 |
| Giebenhain, M | 1 |
| Stolee, A | 1 |
| Notation, A | 1 |
| Dixon, R | 1 |
| Blackard, CE | 1 |
| Riessbeck, KH | 1 |
| Gittes, RF | 1 |
| Baillie, AH | 1 |
| Mack, WS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase IIa Clinical Trial to Evaluate Pharmacokinetics and Safety of Slow Release DHEA[NCT05623059] | Phase 1/Phase 2 | 9 participants (Anticipated) | Interventional | 2023-03-03 | Recruiting | ||
| MOSAIC-P: Mindfulness Online for Symptom Alleviation and Improvement in Cancer of the Prostate[NCT03853902] | 30 participants (Actual) | Interventional | 2016-01-26 | Completed | |||
| Randomized Controlled Trial Comparing Mindfulness-Based Stress Reduction (MBSR) to Supportive-Expressive Therapy (SET) on Psychological and Biological Outcomes in Breast Cancer Patients[NCT00390169] | Phase 3 | 300 participants (Anticipated) | Interventional | 2006-10-31 | Active, not recruiting | ||
| Mind-Body Health in Uro-Oncology: A Randomized Controlled Trial[NCT03852030] | 120 participants (Actual) | Interventional | 2012-07-31 | Completed | |||
| Reducing the Effects of Active Surveillance Stress, Uncertainty and Rumination Thru Engagement in Mindfulness Education[NCT02871752] | 225 participants (Actual) | Interventional | 2016-08-10 | Completed | |||
| Who Benefits More? Optimising Mindfulness Based Interventions for Improved Psychological Outcomes[NCT04417153] | 1,000 participants (Anticipated) | Observational | 2019-09-20 | Recruiting | |||
| REDEFINE AYAO: Reducing Emotional Distress, Enhancing Function and Improving Network Engagement in Adolescent and Young Adult Oncology[NCT02495376] | 151 participants (Actual) | Interventional | 2014-06-30 | Completed | |||
| The Effect of Male Hormonal Contraceptive Regimens on Prostate Tissue In Normal Men[NCT00490555] | Phase 2/Phase 3 | 32 participants (Actual) | Interventional | 2009-01-31 | Completed | ||
| The Effects of Testosterone on Prostate Tissue in Normal Men (ACYP-1)[NCT00161486] | Phase 1 | 13 participants (Actual) | Interventional | 2004-07-31 | Completed | ||
| Testosterone Replacement and Dutasteride Effectiveness (TRADE)[NCT00194675] | Phase 4 | 53 participants (Actual) | Interventional | 2005-03-31 | Completed | ||
| The Effect of Dihydrotestosterone (DHT) on Prostate Tissue Androgen Concentrations and Inflammation in Normal Men[NCT00490022] | Phase 1/Phase 2 | 31 participants (Actual) | Interventional | 2007-06-30 | Completed | ||
| Effect of DHEA on Skin Aging - Placebo-Controlled and Randomized Phase III Study in Postmenopausal Women.[NCT00248989] | Phase 3 | 150 participants (Actual) | Interventional | 2004-11-01 | Completed | ||
| Phase II-III Placebo-Controlled, Study to Evaluate the Effects of DHEA on Vasomotor Symptoms (Hot Flashes) in Postmenopausal Women[NCT00317148] | Phase 2/Phase 3 | 50 participants (Actual) | Interventional | 2005-08-31 | Completed | ||
| A Placebo-controlled Study Examining the Morphological/Biochemical Effects of Intrarosa on the Vulvar Vestibule and Vagina in Women With Genitourinary Syndrome of Menopause/Vulvovaginal Atrophy[NCT03782480] | Phase 3 | 40 participants (Anticipated) | Interventional | 2019-03-02 | Recruiting | ||
| Mechanisms of Hormonal Control of Spermatogenesis in Man[NCT02147964] | Phase 2 | 0 participants (Actual) | Interventional | 2019-06-30 | Withdrawn (stopped due to No funding was obtained for this study.) | ||
| Mechanisms of Control of the Intratesticular Hormonal Milieu in Man[NCT01215292] | Phase 1/Phase 2 | 46 participants (Actual) | Interventional | 2011-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00490555)
Timeframe: 10 weeks
| Intervention | ng/mL (Median) |
|---|---|
| 1) Placebo | 0.9 |
| 2) Testosterone Gel | 0.9 |
| 3) T Gel +Dutasteride | 1.8 |
| 4) T Gel+ DMPA | 0.7 |
(NCT00490555)
Timeframe: 10 weeks
| Intervention | ng/mL (Median) |
|---|---|
| 1) Placebo | 4.3 |
| 2) Testosterone Gel | 3.5 |
| 3) T Gel +Dutasteride | 3.8 |
| 4) T Gel+ DMPA | 3.2 |
(NCT00490555)
Timeframe: 10 weeks
| Intervention | ng/mL (Median) |
|---|---|
| 1) Placebo | 0.5 |
| 2) Testosterone Gel | 1.8 |
| 3) T Gel +Dutasteride | 0.5 |
| 4) T Gel+ DMPA | 0.6 |
PSA level week 10 end of treatment (NCT00490555)
Timeframe: 10 weeks
| Intervention | ng/mL (Median) |
|---|---|
| 1) Placebo | 0.8 |
| 2) Testosterone Gel | 0.9 |
| 3) T Gel +Dutasteride | 0.7 |
| 4) T Gel+ DMPA | 0.4 |
(NCT00490555)
Timeframe: 10 weeks
| Intervention | ng/mL (Median) |
|---|---|
| 1) Placebo | 4.0 |
| 2) Testosterone Gel | 4.4 |
| 3) T Gel +Dutasteride | 7.0 |
| 4) T Gel+ DMPA | 1.8 |
(NCT00194675)
Timeframe: Baseline, Month 6
| Intervention | cubic centimeters (Mean) | |
|---|---|---|
| Baseline, Day 0 | Month 6 | |
| Testosterone Gel + Oral Dutasteride | 44.4 | 38.6 |
| Testosterone Gel + Oral Placebo | 54.2 | 58.3 |
(NCT00194675)
Timeframe: Baseline, Month 6
| Intervention | ng/ ml (Mean) | |
|---|---|---|
| Baseline PSA | Month 6 PSA | |
| Testosterone Gel + Oral Dutasteride | 2.1 | 1.4 |
| Testosterone Gel + Oral Placebo | 2.8 | 3.1 |
(NCT00194675)
Timeframe: Baseline, 3-months, 6-months
| Intervention | ng/ dL (Mean) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total testosterone, baseline | Total testosterone, month 3 | Total testosterone, month 6 | Free testosterone, baseline | Free testosterone, month 3 | Free testosterone, month 6 | Dihydrotestosterone (DHT), baseline | Dihydrotestosterone (DHT), month 3 | Dihydrotestosterone (DHT), month 6 | Dehydroepiandrosterone (DHEA), baseline | Dehydroepiandrosterone (DHEA), month 3 | Dehydroepiandrosterone (DHEA), month 6 | Androstenedione, baseline | Androstenedione, month 3 | Androstenedione, month 6 | |
| Testosterone Gel + Oral Dutasteride | 213 | 525 | 534 | 4.5 | 12.0 | 12.3 | 28 | 16 | 12 | 99 | 109 | 111 | 47 | 140 | 123 |
| Testosterone Gel + Oral Placebo | 206 | 494 | 481 | 4.2 | 11.3 | 11.4 | 47 | 145 | 134 | 72 | 98 | 97 | 45 | 99 | 100 |
(NCT00194675)
Timeframe: Baseline, 3-months, 6-months
| Intervention | cc (Mean) | ||
|---|---|---|---|
| Baseline Post Residual Volume (PVR) | 3 month Post Residual Volume | 6 month Post Residual Volume | |
| Testosterone Gel + Oral Dutasteride | 48 | 41 | 32 |
| Testosterone Gel + Oral Placebo | 43 | 36 | 39 |
(NCT00194675)
Timeframe: Baseline, 3-months, 6-months
| Intervention | cc/sec (Mean) | ||
|---|---|---|---|
| Baseline Uroflow, Baseline | Uroflow after 3 months of treatment | Uroflow after 6 months of treatment | |
| Testosterone Gel + Oral Dutasteride | 13.4 | 13.2 | 14.6 |
| Testosterone Gel + Oral Placebo | 13.8 | 12.7 | 13.8 |
International Prostate Symptom Score to assess lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH). Minimum score = 0, maximum score = 35; mildly symptomatic score = 0-7; moderately symptomatic score = 8-19; severely symptomatic score = 20-35; no subscales. (NCT00194675)
Timeframe: Baseline, Month 3, Month 6
| Intervention | score (Mean) | ||
|---|---|---|---|
| Baseline IPSS | Month 3- IPSS | Month 6 IPSS | |
| Testosterone Gel + Oral Dutasteride | 13.3 | 10.2 | 10.3 |
| Testosterone Gel + Oral Placebo | 13.5 | 11.6 | 11.1 |
Prostate epithelial cell proliferation in the prostate biopsy tissue was measured using Ki-67 immunohistochemical staining of prostate epithelium as a marker of cell proliferation (values are number of Ki-67 positive stained cells per 100 prostate epithelial cells). The placebo and treatment groups were compared. (NCT00490022)
Timeframe: 28-days
| Intervention | #pos.Ki-67cells per100 prst. epth cells (Mean) |
|---|---|
| Placebo DHT Gel | 1.3 |
| DHT Gel | 0.7 |
After 4 weeks of either daily dihydrotestosterone transdermal gel or placebo gel, subjects underwent a prostate biopsy. Intraprostatic hormone concentrations, specifically DHT and Testosterone, were measured. Unit of measure is ng/g. (NCT00490022)
Timeframe: 28-days
| Intervention | ng/g (Mean) | |
|---|---|---|
| DHT concentrations | Testosterone Concentrations | |
| DHT Gel | 3.1 | 0.4 |
| Placebo DHT Gel | 2.8 | 0.6 |
(NCT01215292)
Timeframe: 10 days
| Intervention | ng/mL (Median) |
|---|---|
| Acyline + Testosterone Gel (Tgel)+ Placebo | .87 |
| Acyline + Tgel + Ketoconazole 400mg | 0.5 |
| Acyline + Tgel + Ketoconazole 800mg | 0.12 |
| Acyline & TGel & Dutasteride 2.5mg | 1.7 |
| Acyline & TGel & Anastrazole 1mg | 3.6 |
(NCT01215292)
Timeframe: 10 days
| Intervention | ng/mL (Median) |
|---|---|
| Acyline + Testosterone Gel (Tgel)+ Placebo | 3.17 |
| Acyline & TGel & Ketoconazole 400 mg | 2.08 |
| Acyline & TGel & Ketoconazole 800 mg | 1.46 |
| Acyline & TGel & Dutasteride | 0.12 |
| Acyline & TGel & Anastrazole | 3.63 |
(NCT01215292)
Timeframe: 10 days
| Intervention | ng/mL (Median) |
|---|---|
| Acyline + Testosterone Gel + Placebo | 14 |
| Acyline + Tgel + Ketoconazole 400mg | 3.7 |
| Acyline + Tgel + Ketoconazole 800mg | 1.7 |
| Acyline & TGel & Dutasteride 2.5mg | 18.4 |
| Acyline & TGel & Anastrazole 1mg | 24.0 |
21 reviews available for dehydroepiandrosterone and Prostatic Neoplasms
| Article | Year |
|---|---|
Nutraceuticals and Phytotherapy in Men's Health: Antioxidants, Pro-oxidants, and a Novel Opportunity for Lifestyle Changes.
Topics: Antioxidants; Dehydroepiandrosterone; Dietary Supplements; Female; Humans; Life Style; Male; Men's H | 2022 |
The importance of targeting intracrinology in prostate cancer management.
Topics: Abiraterone Acetate; Androgen Antagonists; Androgens; Antineoplastic Agents; Benzamides; Dehydroepia | 2019 |
[Advances in the study of steroidal inhibitors of cytochrome P45017alpha].
Topics: Androstenedione; Androstenes; Androstenols; Animals; Antineoplastic Agents; Dehydroepiandrosterone; | 2013 |
[CYP17A1 inhibitors in prostate cancer: mechanisms of action independent of the androgenic pathway].
Topics: Abiraterone Acetate; Adjuvants, Immunologic; Androgens; Androstadienes; Androstenedione; Antineoplas | 2013 |
Reconsideration of progression to CRPC during androgen deprivation therapy.
Topics: Androgen Antagonists; Androgens; Dehydroepiandrosterone; Disease Progression; Docetaxel; Humans; Mal | 2015 |
Combined blockade of testicular and locally made androgens in prostate cancer: a highly significant medical progress based upon intracrinology.
Topics: Androgen Antagonists; Androgens; Androstenes; Androstenols; Animals; Antineoplastic Agents; Benzamid | 2015 |
DHEA metabolism in prostate: For better or worse?
Topics: Dehydroepiandrosterone; Epithelium; Humans; Male; Prostate; Prostatic Neoplasms; Risk Factors; Strom | 2009 |
Clinical implications of the 5α-androstanedione pathway for castration-resistant prostate cancer.
Topics: 3-Hydroxysteroid Dehydrogenases; Abiraterone Acetate; Androstadienes; Androstenediol; Antineoplastic | 2011 |
[The alternative androgen synthesis pathway in humans].
Topics: 17-alpha-Hydroxypregnenolone; 17-alpha-Hydroxyprogesterone; Adrenal Glands; Adrenal Hyperplasia, Con | 2013 |
[DHEA: desire and resistance].
Topics: Aged; Aging; Breast Neoplasms; Dehydroepiandrosterone; Erectile Dysfunction; Female; Humans; Libido; | 2002 |
Prevention of prostate cancer by androgens: experimental paradox or clinical reality.
Topics: Adult; Aged; Aged, 80 and over; Androgens; Animals; Apoptosis; Cell Differentiation; Cell Proliferat | 2004 |
Steroids as procarcinogenic agents.
Topics: Androgens; Breast Neoplasms; Carcinogens; Cell Line, Tumor; Cytochrome P-450 CYP1A1; Cytochrome P-45 | 2004 |
C(19)-5-ene steroids in nature.
Topics: Androstenediol; Animals; Dehydroepiandrosterone; Female; Health Status; Humans; Immunity; Male; Pros | 2005 |
Does DHEA exert direct effects on androgen and estrogen receptors, and does it promote or prevent prostate cancer?
Topics: Dehydroepiandrosterone; Humans; Male; Prostatic Neoplasms; Receptors, Androgen; Receptors, Estrogen | 2005 |
Is dehydroepiandrosterone a hormone?
Topics: Adult; Aged; Androgen Antagonists; Animals; Breast; Breast Neoplasms; Castration; Dehydroepiandroste | 2005 |
[Keyrole of endocrinology in the victory against prostate cancer].
Topics: Adrenal Glands; Androgen Antagonists; Antineoplastic Agents, Hormonal; Dehydroepiandrosterone; Fluta | 2006 |
["Intracrinology". Autonomy and freedom of peripheral tissues].
Topics: 17-Hydroxysteroid Dehydrogenases; 3-Hydroxysteroid Dehydrogenases; 3-Oxo-5-alpha-Steroid 4-Dehydroge | 1995 |
Use of DHEA in a patient with advanced prostate cancer: a case report and review.
Topics: Aged; Dehydroepiandrosterone; Humans; Male; Neoplasm Staging; Prostatic Neoplasms | 1997 |
Effect of a vegetarian diet and dexamethasone on plasma prolactin, testosterone and dehydroepiandrosterone in men and women.
Topics: Adult; Breast Neoplasms; Circadian Rhythm; Dehydroepiandrosterone; Dexamethasone; Diet; Diet, Vegeta | 1979 |
Intracrinology.
Topics: Adrenal Glands; Androgens; Breast Neoplasms; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; | 1991 |
Intracrinology.
Topics: Adrenal Glands; Androgens; Breast Neoplasms; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; | 1991 |
Intracrinology.
Topics: Adrenal Glands; Androgens; Breast Neoplasms; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; | 1991 |
Intracrinology.
Topics: Adrenal Glands; Androgens; Breast Neoplasms; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; | 1991 |
Intracrinology.
Topics: Adrenal Glands; Androgens; Breast Neoplasms; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; | 1991 |
Intracrinology.
Topics: Adrenal Glands; Androgens; Breast Neoplasms; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; | 1991 |
Intracrinology.
Topics: Adrenal Glands; Androgens; Breast Neoplasms; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; | 1991 |
Intracrinology.
Topics: Adrenal Glands; Androgens; Breast Neoplasms; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; | 1991 |
Intracrinology.
Topics: Adrenal Glands; Androgens; Breast Neoplasms; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; | 1991 |
Adrenal androgen blockade in relapsed prostate cancer.
Topics: Adrenalectomy; Aminoglutethimide; Androgen Antagonists; Castration; Combined Modality Therapy; Cypro | 1985 |
9 trials available for dehydroepiandrosterone and Prostatic Neoplasms
112 other studies available for dehydroepiandrosterone and Prostatic Neoplasms
| Article | Year |
|---|---|
Urinary androgens excretion patterns and prostate cancer in Mexican men.
Topics: Androgens; Carcinogenesis; Chromatography, Liquid; Dehydroepiandrosterone; Humans; Male; Prostatic N | 2021 |
In Vitro Analysis of Deoxynivalenol Influence on Steroidogenesis in Prostate.
Topics: Cell Line; Cell Line, Tumor; Dehydroepiandrosterone; Estradiol; Gene Expression Regulation; Humans; | 2021 |
Sex steroid hormones in urinary exosomes as biomarkers for the prediction of prostate cancer.
Topics: Androstenedione; Biomarkers; Dehydroepiandrosterone; Dihydrotestosterone; Exosomes; Humans; Male; Pr | 2022 |
Extensive Alteration of Androgen Precursor Levels After Castration in Prostate Cancer Patients and Their Association With Active Androgen Level.
Topics: Androgen Antagonists; Androgens; Androstenedione; Androsterone; Dehydroepiandrosterone; Dihydrotesto | 2022 |
A high serum dehydroepiandrosterone concentration is a predictor of candidates for active surveillance in men with serum prostate-specific antigen < 10 ng/mL.
Topics: Aged; Chromatography, Liquid; Dehydroepiandrosterone; Humans; Male; Predictive Value of Tests; Prost | 2022 |
3βHSD activity saturates at physiological substrate concentrations in intact cells.
Topics: Androgens; Androstenediols; Androstenedione; Cell Line, Tumor; Dehydroepiandrosterone; Humans; Male; | 2023 |
Plasma Androstenedione Concentration Can Discriminate Frail versus Non-Frail Men with Prostate Cancer under Androgen Deprivation Therapy.
Topics: Aged; Androgen Antagonists; Androgens; Androstenedione; Dehydroepiandrosterone; Frail Elderly; Frail | 2023 |
Prospective evaluation of urinary steroids and prostate carcinoma-induced deviation: preliminary results.
Topics: Aged; Biomarkers; Dehydroepiandrosterone; Etiocholanolone; Gas Chromatography-Mass Spectrometry; Hum | 2021 |
Slow-, Tight-Binding Inhibition of CYP17A1 by Abiraterone Redefines Its Kinetic Selectivity and Dosing Regimen.
Topics: Androstenes; Cell Line, Tumor; Dehydroepiandrosterone; Enzyme Inhibitors; Humans; Kinetics; Male; Pr | 2020 |
Steroid Sulfatase Stimulates Intracrine Androgen Synthesis and is a Therapeutic Target for Advanced Prostate Cancer.
Topics: Androgen Antagonists; Androgens; Androstenes; Benzamides; Carcinogenesis; Cell Line, Tumor; Cell Pro | 2020 |
Tracing steroidogenesis in prostate biopsy samples to unveil prostate tissue androgen metabolism characteristics and potential clinical application.
Topics: Aged; Aged, 80 and over; Androgens; Biopsy; Cell Line, Tumor; Chromatography, High Pressure Liquid; | 2021 |
Osteoblasts Generate Testosterone From DHEA and Activate Androgen Signaling in Prostate Cancer Cells.
Topics: Androgens; Animals; Cell Line, Tumor; Dehydroepiandrosterone; Humans; Male; Mice; Osteoblasts; Prost | 2021 |
AR Signaling in Prostate Cancer Regulates a Feed-Forward Mechanism of Androgen Synthesis by Way of HSD3B1 Upregulation.
Topics: Androgens; Androstenedione; Animals; Antineoplastic Agents, Hormonal; Benzamides; Cell Line, Tumor; | 2018 |
Adrenal androgens rescue prostatic dihydrotestosterone production and growth of prostate cancer cells after castration.
Topics: Adrenal Glands; Androgens; Animals; Cell Line, Tumor; Cell Proliferation; Dehydroepiandrosterone; De | 2019 |
Androgen deprivation promotes intratumoral synthesis of dihydrotestosterone from androgen metabolites in prostate cancer.
Topics: 17-Hydroxysteroid Dehydrogenases; Aged; Androgens; Androstane-3,17-diol; Cell Line, Tumor; Dehydroep | 2013 |
Differential effects of dehydroepiandrosterone and testosterone in prostate and colon cancer cell apoptosis: the role of nerve growth factor (NGF) receptors.
Topics: Animals; Apoptosis; Cell Proliferation; Colonic Neoplasms; Dehydroepiandrosterone; Humans; Male; Ner | 2013 |
TGFβ1 alters androgenic metabolites and hydroxysteroid dehydrogenase enzyme expression in human prostate reactive stromal primary cells: Is steroid metabolism altered by prostate reactive stromal microenvironment?
Topics: 17-Hydroxysteroid Dehydrogenases; 3-Hydroxysteroid Dehydrogenases; Androstenedione; Cell Line, Tumor | 2013 |
Vitamin D receptor agonist EB1089 is a potent regulator of prostatic "intracrine" metabolism.
Topics: Androgens; Calcitriol; Cell Line, Tumor; Cell Proliferation; Cytochrome P-450 CYP3A; Cytochrome P-45 | 2014 |
Androgenic biomarker prof|ling in human matrices and cell culture samples using high throughput, electrospray tandem mass spectrometry.
Topics: Androgens; Biomarkers; Chromatography, High Pressure Liquid; Dehydroepiandrosterone; Dihydrotestoste | 2014 |
Effect of dehydroepiandrosterone derivatives on the activity of 5α-reductase isoenzymes and on cancer cell line PC-3.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cells, Cultured; Cholestenone 5 alpha-Reductase; C | 2014 |
Combined inhibition of glycolysis, the pentose cycle, and thioredoxin metabolism selectively increases cytotoxicity and oxidative stress in human breast and prostate cancer.
Topics: Antioxidants; Breast Neoplasms; Cell Line, Tumor; Dehydroepiandrosterone; Deoxyglucose; Drug Synergi | 2015 |
Low serum dehydroepiandrosterone examined by liquid chromatography-tandem mass spectrometry correlates with poor prognosis in hormone-naïve prostate cancer.
Topics: Aged; Biopsy, Needle; Chromatography, Liquid; Dehydroepiandrosterone; Humans; Male; Middle Aged; Neo | 2016 |
Human prostate stromal cells stimulate increased PSA production in DHEA-treated prostate cancer epithelial cells.
Topics: Cell Line, Tumor; Cell Proliferation; Coculture Techniques; Dehydroepiandrosterone; Epithelial Cells | 2008 |
Endocrine-immune-paracrine interactions in prostate cells as targeted by phytomedicines.
Topics: Adjuvants, Immunologic; Cells, Cultured; Coculture Techniques; Dehydroepiandrosterone; Endocrine Sys | 2009 |
Prostate cancer stromal cells and LNCaP cells coordinately activate the androgen receptor through synthesis of testosterone and dihydrotestosterone from dehydroepiandrosterone.
Topics: Blotting, Western; Bone and Bones; Cell Line, Tumor; Cell Proliferation; Chromatography, Liquid; Coc | 2009 |
3beta-hydroxysteroid dehydrogenase is a possible pharmacological target in the treatment of castration-resistant prostate cancer.
Topics: 17-Hydroxysteroid Dehydrogenases; Antineoplastic Agents; Carcinoma; Cell Line, Tumor; Cell Nucleus; | 2010 |
Cannabinoid receptor-dependent and -independent anti-proliferative effects of omega-3 ethanolamides in androgen receptor-positive and -negative prostate cancer cell lines.
Topics: Adjuvants, Immunologic; Amidohydrolases; Animals; Apoptosis; Blotting, Western; Cell Cycle; Cell Mem | 2010 |
Trilostane, an inhibitor of 3β-hydroxysteroid dehydrogenase, has an agonistic activity on androgen receptor in human prostate cancer cells.
Topics: 3-Hydroxysteroid Dehydrogenases; Androgens; Cell Line, Tumor; Chromatography, Liquid; Dehydroepiandr | 2010 |
Effect of castration monotherapy on the levels of adrenal androgens in cancerous prostatic tissues.
Topics: Adrenal Glands; Androgens; Androstenediol; Androstenedione; Castration; Chromatography, Liquid; Dehy | 2011 |
Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors.
Topics: Androstenedione; Androstenes; Androstenols; Animals; Antineoplastic Agents, Hormonal; Carcinoma; Cel | 2011 |
Discovery of orteronel (TAK-700), a naphthylmethylimidazole derivative, as a highly selective 17,20-lyase inhibitor with potential utility in the treatment of prostate cancer.
Topics: Animals; Antineoplastic Agents; Crystallography, X-Ray; Dehydroepiandrosterone; Enzyme Inhibitors; H | 2011 |
Effect of Roux-en-Y gastric bypass on testosterone and prostate-specific antigen.
Topics: Body Mass Index; Dehydroepiandrosterone; Delayed Diagnosis; Gastric Bypass; Humans; Male; Middle Age | 2012 |
Abiraterone inhibits 3β-hydroxysteroid dehydrogenase: a rationale for increasing drug exposure in castration-resistant prostate cancer.
Topics: 3-Hydroxysteroid Dehydrogenases; Abiraterone Acetate; Active Transport, Cell Nucleus; Androstadienes | 2012 |
Aldo-keto reductase family 1 member C3 (AKR1C3) is a biomarker and therapeutic target for castration-resistant prostate cancer.
Topics: 3-Hydroxysteroid Dehydrogenases; Aldo-Keto Reductase Family 1 Member C3; Apoptosis; Biomarkers, Tumo | 2013 |
3 beta-acetoxyandrost-1,5-diene-17-ethylene ketal functions as a potent antiandrogen with marginal agonist activity.
Topics: Androgen Antagonists; Androstadienes; Cell Division; Dehydroepiandrosterone; Genes, Reporter; Humans | 2003 |
A STUDY OF STEROID EXCRETION IN PATIENTS WITH PROSTATIC CANCER.
Topics: 17-Ketosteroids; Adrenal Cortex Hormones; Androsterone; Biopsy; Cortisone; Dehydroepiandrosterone; D | 1964 |
Enhanced androgen receptor signaling correlates with the androgen-refractory growth in a newly established MDA PCa 2b-hr human prostate cancer cell subline.
Topics: Androgen Antagonists; Androgens; Anilides; Animals; Cell Division; Dehydroepiandrosterone; Humans; M | 2003 |
[Change of serum adrenal androgens in prostatic cancer patients after bilateral orchidectomy or LHRH agonist treatment].
Topics: Adrenocorticotropic Hormone; Aged; Aged, 80 and over; Androgens; Dehydroepiandrosterone; Follicle St | 2003 |
The androgen axis in recurrent prostate cancer.
Topics: Aged; Aged, 80 and over; Androgens; Androstenedione; Antibodies, Monoclonal; Cell Nucleus; Dehydroep | 2004 |
Prostate intraepithelial neoplasia in Noble rats, a potential intermediate endpoint for chemoprevention studies.
Topics: Animals; Antineoplastic Agents; Dehydroepiandrosterone; Dose-Response Relationship, Drug; Drug Scree | 2004 |
Comparative effects of DHEA vs. testosterone, dihydrotestosterone, and estradiol on proliferation and gene expression in human LNCaP prostate cancer cells.
Topics: Blotting, Western; Cell Line, Tumor; Cell Proliferation; Dehydroepiandrosterone; Dihydrotestosterone | 2005 |
Chemoprevention of rat prostate carcinogenesis by dietary 16alpha-fluoro-5-androsten-17-one (fluasterone), a minimally androgenic analog of dehydroepiandrosterone.
Topics: Animals; Cell Transformation, Neoplastic; Chemoprevention; Dehydroepiandrosterone; Male; Prostatic N | 2007 |
Dose effect of soy supplementation in prostate cancer: a pilot study.
Topics: Dehydroepiandrosterone; Dietary Supplements; Dose-Response Relationship, Drug; Estrogens; Humans; Im | 2006 |
Androgen receptor or estrogen receptor-beta blockade alters DHEA-, DHT-, and E(2)-induced proliferation and PSA production in human prostate cancer cells.
Topics: Androgen Antagonists; Androgen Receptor Antagonists; Anilides; Cell Division; Cell Line, Tumor; Dehy | 2007 |
Endocrine and immune responses to resistance training in prostate cancer patients.
Topics: Adenocarcinoma; Androgen Antagonists; Antineoplastic Agents, Hormonal; Biomarkers; Bone Remodeling; | 2008 |
Synthesis and evaluation of novel 17-indazole androstene derivatives designed as CYP17 inhibitors.
Topics: Binding, Competitive; Cell Line, Tumor; Cell Proliferation; Dehydroepiandrosterone; Humans; Male; Pr | 2007 |
Prediagnostic C-peptide and risk of prostate cancer.
Topics: Biomarkers, Tumor; C-Peptide; Case-Control Studies; Dehydroepiandrosterone; Early Diagnosis; Follow- | 2007 |
Inhibition of basal and adrenocorticotropin-stimulated plasma levels of adrenal androgens after treatment with an antiandrogen in castrated patients with prostatic cancer.
Topics: Adrenocorticotropic Hormone; Aged; Androgen Antagonists; Androgens; Buserelin; Castration; Combined | 1984 |
Effect of diet on plasma and urinary hormones in South African black men with prostatic cancer.
Topics: Aged; Androgens; Androsterone; Black People; Dehydroepiandrosterone; Diet; Estriol; Estrogens; Estro | 1982 |
Plasma androgen levels after subcapsular orchiectomy or estrogen treatment for prostatic carcinoma.
Topics: Androgens; Castration; Dehydroepiandrosterone; Estradiol; Estradiol Congeners; Humans; Male; Prostat | 1982 |
Orchiectomy does not selectively increase adrenal androgen concentrations.
Topics: Adrenal Glands; Aged; Androgens; Castration; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; | 1984 |
Response to aminoglutethimide and cortisone acetate in advanced prostatic cancer.
Topics: Adenocarcinoma; Aged; Aminoglutethimide; Androstenedione; Antineoplastic Combined Chemotherapy Proto | 1984 |
Acute infusion of hCG and thyroid hormone pattern before and after bilateral orchiectomy.
Topics: Aged; Castration; Chorionic Gonadotropin; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; Hu | 1984 |
Ketoconazole therapy in advanced prostatic cancer.
Topics: Acid Phosphatase; Aged; Androstenedione; Dehydroepiandrosterone; Follow-Up Studies; Humans; Ketocona | 1984 |
Long-term effects of endocrine treatment on serum steroids in advanced prostatic carcinoma patients.
Topics: Aged; Androstenedione; Androsterone; Castration; Dehydroepiandrosterone; Dihydrotestosterone; Estrad | 1980 |
[Endocrinological studies on prostatic carcinoma. 1. Plasma hormone profiles in patients with prostatic carcinoma (author's transl)].
Topics: Aged; Androgens; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; Gonadotropins, Pituitary; H | 1981 |
Basis for hormonal management of advanced prostate cancer.
Topics: Androstenedione; Animals; Dehydroepiandrosterone; Dihydrotestosterone; Humans; Male; Neoplasm Recurr | 1993 |
Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone.
Topics: Adrenal Glands; Aged; Amino Acid Sequence; Androgen Antagonists; Androstenedione; Animals; Base Sequ | 1993 |
Seasonal variation in vitamin D, vitamin D-binding protein, and dehydroepiandrosterone: risk of prostate cancer in black and white men.
Topics: Adult; Aged; Black People; Case-Control Studies; Dehydroepiandrosterone; Ergocalciferols; Humans; Li | 1995 |
Dehydroepiandrosterone (DHEA).
Topics: Body Composition; Clinical Trials as Topic; Dehydroepiandrosterone; Female; Hirsutism; HIV-1; Humans | 1996 |
Dehydroepiandrosterone activates mutant androgen receptors expressed in the androgen-dependent human prostate cancer xenograft CWR22 and LNCaP cells.
Topics: Androgen Antagonists; Animals; Chromosome Mapping; Dehydroepiandrosterone; Epithelium; Estradiol; Fl | 1997 |
Prostatic cancer 30 years after bilateral orchidectomy.
Topics: Adenocarcinoma; Aged; Dehydroepiandrosterone; Fatal Outcome; Humans; Male; Orchiectomy; Penile Neopl | 1998 |
Dehydroepiandrosterone, insulin-like growth factor-I, and prostate cancer.
Topics: Aged; Dehydroepiandrosterone; Dietary Supplements; Humans; Insulin-Like Growth Factor I; Male; Middl | 1998 |
Chemoprevention of hormone-dependent prostate cancer in the Wistar-Unilever rat.
Topics: Alitretinoin; Animals; Antineoplastic Agents; Dehydroepiandrosterone; Disease Models, Animal; Immuno | 1999 |
Growth of HPV-18 immortalized human prostatic intraepithelial neoplasia cell lines. Influence of IL-10, follistatin, activin-A, and DHT.
Topics: Activins; Adjuvants, Immunologic; Androgens; Animals; Blotting, Western; Cell Adhesion; Cell Divisio | 1999 |
Chemoprevention of rat prostate carcinogenesis by early and delayed administration of dehydroepiandrosterone.
Topics: Adenocarcinoma; Administration, Oral; Animals; Anticarcinogenic Agents; Carcinoma; Cyproterone Aceta | 1999 |
Suppression of Delta(5)-androstenediol-induced androgen receptor transactivation by selective steroids in human prostate cancer cells.
Topics: Androstenediol; Dehydroepiandrosterone; Dihydrotestosterone; Humans; Male; Prostatic Neoplasms; Rece | 1999 |
Endocrine patterns in patients with benign and malignant prostatic diseases.
Topics: Aged; Biopsy; Dehydroepiandrosterone; Estradiol; Fluorescence Polarization; Follicle Stimulating Hor | 2000 |
High-grade prostate cancer is associated with low serum testosterone levels.
Topics: Adult; Aged; Dehydroepiandrosterone; Estradiol; Follicle Stimulating Hormone; Humans; Hypothalamo-Hy | 2001 |
High-grade prostate cancer is associated with low serum testosterone levels.
Topics: Adult; Aged; Dehydroepiandrosterone; Estradiol; Follicle Stimulating Hormone; Humans; Hypothalamo-Hy | 2001 |
High-grade prostate cancer is associated with low serum testosterone levels.
Topics: Adult; Aged; Dehydroepiandrosterone; Estradiol; Follicle Stimulating Hormone; Humans; Hypothalamo-Hy | 2001 |
High-grade prostate cancer is associated with low serum testosterone levels.
Topics: Adult; Aged; Dehydroepiandrosterone; Estradiol; Follicle Stimulating Hormone; Humans; Hypothalamo-Hy | 2001 |
High-grade prostate cancer is associated with low serum testosterone levels.
Topics: Adult; Aged; Dehydroepiandrosterone; Estradiol; Follicle Stimulating Hormone; Humans; Hypothalamo-Hy | 2001 |
High-grade prostate cancer is associated with low serum testosterone levels.
Topics: Adult; Aged; Dehydroepiandrosterone; Estradiol; Follicle Stimulating Hormone; Humans; Hypothalamo-Hy | 2001 |
High-grade prostate cancer is associated with low serum testosterone levels.
Topics: Adult; Aged; Dehydroepiandrosterone; Estradiol; Follicle Stimulating Hormone; Humans; Hypothalamo-Hy | 2001 |
High-grade prostate cancer is associated with low serum testosterone levels.
Topics: Adult; Aged; Dehydroepiandrosterone; Estradiol; Follicle Stimulating Hormone; Humans; Hypothalamo-Hy | 2001 |
High-grade prostate cancer is associated with low serum testosterone levels.
Topics: Adult; Aged; Dehydroepiandrosterone; Estradiol; Follicle Stimulating Hormone; Humans; Hypothalamo-Hy | 2001 |
2-difluoromethylornithine and dehydroepiandrosterone inhibit mammary tumor progression but not mammary or prostate tumor initiation in C3(1)/SV40 T/t-antigen transgenic mice.
Topics: Animals; Anticarcinogenic Agents; Antigens, Polyomavirus Transforming; Apoptosis; Cell Division; Deh | 2001 |
Moderate dose diethylstilbestrol diphosphate therapy in hormone refractory prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Dehydroepiandrosterone; De | 2001 |
Suppression of plasma androgens by spironolactone in castrated men with carcinoma of the prostate.
Topics: Aged; Androgens; Androstenedione; Castration; Dehydroepiandrosterone; Depression, Chemical; Humans; | 1975 |
Biosynthesis and metabolism of androgenic hormones in cancer of the prostate.
Topics: Adenocarcinoma; Androgens; Androstenedione; Dehydroepiandrosterone; Dihydrotestosterone; Humans; Mal | 1976 |
[Sex hormone balance in prostate cancer].
Topics: 17-Ketosteroids; Aged; Circadian Rhythm; Dehydroepiandrosterone; Estrogens; Humans; Male; Middle Age | 1978 |
Treatment of advanced cancer of prostate with megestrol acetate.
Topics: Acid Phosphatase; Bone and Bones; Dehydroepiandrosterone; Humans; Male; Megestrol; Prostatic Neoplas | 1978 |
Dexamethasone suppressibility of plasma pregnenolone or dehydroepiandrosterone in gonadectomized patients.
Topics: Adrenocorticotropic Hormone; Adult; Aged; Breast Neoplasms; Castration; Dehydroepiandrosterone; Dexa | 1979 |
Dehydroepiandrosterone (DHEA) levels in patients with prostatic cancer, heart diseases and under surgery stress.
Topics: Adult; Aged; Aged, 80 and over; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; Female; Hear | 1992 |
Effects of adrenal androgens on the transplantable human prostate tumor PC-82.
Topics: Androstenedione; Animals; Bromodeoxyuridine; Cell Division; Dehydroepiandrosterone; Humans; Male; Mi | 1992 |
Effect of high-dose medroxyprogesterone acetate on plasma hormone levels and pain relief in patients with advanced prostatic cancer.
Topics: Adrenocorticotropic Hormone; Aged; Antineoplastic Agents; Bone Neoplasms; Dehydroepiandrosterone; De | 1990 |
Effect of suramin on human prostate cancer cells in vitro.
Topics: Adenocarcinoma; Androstenedione; Antineoplastic Agents; Cell Line; Dehydroepiandrosterone; Dehydroep | 1991 |
Megestrol acetate plus low-dose estrogen in the management of advanced prostatic carcinoma.
Topics: Androgens; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; Diethylstilbestrol; Drug Therapy, | 1991 |
Pharmacia Award 1990. The biological significance of low testosterone levels and of adrenal androgens in transplantable prostate cancer lines.
Topics: Adenocarcinoma; Androstenedione; Animals; Awards and Prizes; Castration; Dehydroepiandrosterone; Eur | 1991 |
Growth-stimulating effect of adrenal androgens on the R3327 Dunning prostatic carcinoma.
Topics: Adenocarcinoma; Androstenedione; Animals; Castration; Dehydroepiandrosterone; Dehydroepiandrosterone | 1991 |
Steroid glucuronides: human circulatory levels and formation by LNCaP cells.
Topics: Adolescent; Adult; Aging; Androstane-3,17-diol; Androstenedione; Child; Child, Preschool; Dehydroepi | 1991 |
Suppression of plasma androgens by the antiandrogen flutamide in prostatic cancer patients treated with Zoladex, a GnRH analogue.
Topics: 17-alpha-Hydroxyprogesterone; Aged; Aged, 80 and over; Androgens; Androstenedione; Anilides; Antineo | 1990 |
Effects of low testosterone levels and of adrenal androgens on growth of prostate tumor models in nude mice.
Topics: Animals; Cell Transformation, Neoplastic; Dehydroepiandrosterone; Dihydrotestosterone; Female; Male; | 1990 |
Effect of oestrogen or cyproterone acetate treatment on adrenocortical function in prostate carcinoma patients.
Topics: Adrenal Cortex; Adrenocorticotropic Hormone; Aged; Circadian Rhythm; Cyproterone; Cyproterone Acetat | 1986 |
[Remarkable pain relief in the treatment with high-dose medroxyprogesterone acetate in advanced prostatic carcinoma].
Topics: Adrenocorticotropic Hormone; Back Pain; Bone and Bones; Bone Neoplasms; Chlormadinone Acetate; Dehyd | 1989 |
A comparison of androgen status in patients with prostatic cancer treated with oral and/or parenteral estrogens or by orchidectomy.
Topics: Administration, Oral; Aged; Androgens; Androstenedione; Dehydroepiandrosterone; Dehydroepiandrostero | 1989 |
Differential metabolism of dehydroepiandrosterone sulfate and estrogen conjugates by normal or malignant AXC/SSh rat prostate cells and effects of these steroid conjugates on cancer cell proliferation in vitro.
Topics: Animals; Cell Division; Cell Line; Clone Cells; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfa | 1988 |
Androgens, adrenal androgen precursors, and their metabolism in untreated primary tumors and lymph node metastases of human prostatic cancer.
Topics: 17-Hydroxysteroid Dehydrogenases; Adrenal Glands; Androgens; Androstenediols; Androstenedione; Aryls | 1988 |
Levels of plasma steroid glucuronides in intact and castrated men with prostatic cancer.
Topics: Aged; Androgens; Androstane-3,17-diol; Androstenediol; Androsterone; Dehydroepiandrosterone; Dihydro | 1986 |
[Hormonal and clinical efficacy of (D-Leu6)-des Gly-NH2(10)-LH.RH ethylamide against prostatic cancer].
Topics: Aged; Antineoplastic Agents; Dehydroepiandrosterone; Drug Administration Schedule; Estradiol; Follic | 1985 |
Differential androgen modulation of AXC/SSh rat prostate cancer cell proliferation in vitro and its antagonism by antiandrogen.
Topics: Androgen Antagonists; Androgens; Animals; Cell Division; Cell Line; Dehydroepiandrosterone; Dehydroe | 1986 |
High-dose ketoconazole therapy in patients with metastatic prostate cancer.
Topics: Adenocarcinoma; Aged; Androstenedione; Combined Modality Therapy; Dehydroepiandrosterone; Dexamethas | 1986 |
Effects of high dose ketoconazole therapy on the main plasma testicular and adrenal steroids in previously untreated prostatic cancer patients.
Topics: 17-alpha-Hydroxyprogesterone; Adrenal Cortex Hormones; Aged; Androgens; Androstenedione; Corticoster | 1986 |
Orchidectomy or oestrogen treatment in prostatic cancer: effects on serum levels of adrenal androgens and related steroids.
Topics: 17-alpha-Hydroxyprogesterone; Adrenal Glands; Aged; Androgens; Androstenedione; Dehydroepiandrostero | 1987 |
Effects of flutamide and aminoglutethimide on plasma 5 alpha-reduced steroid glucuronide concentrations in castrated patients with cancer of the prostate.
Topics: Aged; Aminoglutethimide; Androstane-3,17-diol; Androstanols; Androsterone; Anilides; Dehydroepiandro | 1987 |
Steroid synthesis inhibition by ketoconazole: sites of action.
Topics: 17-alpha-Hydroxyprogesterone; Aged; Aldehyde-Lyases; Androgens; Androstenedione; Chorionic Gonadotro | 1988 |
Steroid synthesis inhibition by ketoconazole: sites of action.
Topics: 17-alpha-Hydroxyprogesterone; Aged; Aldehyde-Lyases; Androgens; Androstenedione; Chorionic Gonadotro | 1988 |
Steroid synthesis inhibition by ketoconazole: sites of action.
Topics: 17-alpha-Hydroxyprogesterone; Aged; Aldehyde-Lyases; Androgens; Androstenedione; Chorionic Gonadotro | 1988 |
Steroid synthesis inhibition by ketoconazole: sites of action.
Topics: 17-alpha-Hydroxyprogesterone; Aged; Aldehyde-Lyases; Androgens; Androstenedione; Chorionic Gonadotro | 1988 |
Hormonal effects of high dose medroxyprogesterone acetate treatment in males with renal or prostatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Carcinoma, Renal Cell; Dehydroepiandrosterone; Estradiol; F | 1988 |
Endocrine effects of combined treatment with an LHRH agonist in association with flutamide in metastatic prostatic carcinoma.
Topics: Adenocarcinoma; Adrenal Cortex Hormones; Androgens; Androstane-3,17-diol; Androstenediol; Androstene | 1988 |
The role of the steroid-sensitive cation-dependent ATPase in human prostatic tissue.
Topics: 17-Hydroxycorticosteroids; Adenosine Triphosphatases; Androgens; Androstanes; Dehydroepiandrosterone | 1972 |
Intracellular distribution and properties of steroid 16-alpha-hydroxylase in human testes.
Topics: Aged; Androgens; Carbon Isotopes; Castration; Chromatography, Thin Layer; Dehydroepiandrosterone; He | 1967 |
Conjugated and unconjugated dehydroepiandrosterone, aetiocholanolone and androsterone in the peripheral plasma of patients with cancer of the breast, ovary, uterus or prostate.
Topics: Adult; Androsterone; Breast Neoplasms; Dehydroepiandrosterone; Etiocholanolone; Female; Humans; Male | 1969 |
[Metabolism of steroids in normal and pathological human adrenal glands].
Topics: Adolescent; Adrenal Cortex Hormones; Adrenal Gland Diseases; Adrenal Glands; Adult; Androgens; Carbo | 1971 |
[In vitro biosynthesis of androgens in testis of subjects with prostatic cancer treated with estrogens and cyproterone acetate].
Topics: 17-Hydroxycorticosteroids; Acetates; Adult; Aged; Androgen Antagonists; Androgens; Androstanes; Dehy | 1970 |
A single method for determination of urine steroids. I. Levels of testosterone, epitestosterone and 17-ketosteroid fractions. II. Specific activities of testosterone, androsterone and etiocholanolone and production rate of testosterone following administr
Topics: 17-Ketosteroids; Adolescent; Adult; Aged; Androsterone; Breast Neoplasms; Carbon Isotopes; Carcinoma | 1970 |
Studies of the human testis. I. Biosynthetic pathways for androgen formation in human testicular tissue in vitro.
Topics: 17-alpha-Hydroxypregnenolone; 17-Ketosteroids; Aged; Androstanes; Carbon Isotopes; Chromatography, P | 1972 |
Stimulation of 16alpha-hydroxylation of dehydroisoandrosterone sulfate by diethylstilbestrol.
Topics: Aged; Carbon Radioisotopes; Dehydroepiandrosterone; Diethylstilbestrol; Humans; Hydroxylation; Male; | 1973 |
[On a functional examination of the adrenal cortex for the purpose of radiotherapy].
Topics: 17-Ketosteroids; Adolescent; Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Adult; Bone Neopl | 1967 |
Inhibition by antiandrogens of the prostatic growth stimulated by adrenal androgens and pituitary prolactin in castrate rats.
Topics: Adrenocorticotropic Hormone; Androgen Antagonists; Androstanes; Animals; Castration; Dehydroepiandro | 1969 |
Hydroxysteroid dehydrogenases in normal and abnormal human testes.
Topics: Adolescent; Adult; Aged; Androgens; Child; Cryptorchidism; Dehydroepiandrosterone; Hernia, Inguinal; | 1966 |